Duncker Streett & Co. Inc. Reduces Position in Pfizer Inc. (NYSE:PFE)


Share on StockTwits

Duncker Streett & Co. Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 62,580 shares of the biopharmaceutical company’s stock after selling 9,520 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Pfizer were worth $2,267,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Baystate Wealth Management LLC grew its holdings in shares of Pfizer by 0.7% in the first quarter. Baystate Wealth Management LLC now owns 36,227 shares of the biopharmaceutical company’s stock valued at $1,313,000 after purchasing an additional 264 shares during the period. Carmichael Hill & Associates Inc. grew its holdings in shares of Pfizer by 1.9% in the first quarter. Carmichael Hill & Associates Inc. now owns 14,768 shares of the biopharmaceutical company’s stock valued at $535,000 after purchasing an additional 270 shares during the period. Detalus Advisors LLC grew its holdings in shares of Pfizer by 1.0% in the first quarter. Detalus Advisors LLC now owns 27,333 shares of the biopharmaceutical company’s stock valued at $990,000 after purchasing an additional 277 shares during the period. Weaver Consulting Group grew its holdings in shares of Pfizer by 5.1% in the fourth quarter. Weaver Consulting Group now owns 5,791 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 281 shares during the period. Finally, Krilogy Financial LLC grew its holdings in shares of Pfizer by 2.3% in the first quarter. Krilogy Financial LLC now owns 12,390 shares of the biopharmaceutical company’s stock valued at $449,000 after purchasing an additional 283 shares during the period. 67.36% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:PFE opened at $40.05 on Tuesday. The firm’s 50 day moving average price is $37.02 and its 200 day moving average price is $36.78. The stock has a market cap of $223.38 billion, a price-to-earnings ratio of 25.70, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70. Pfizer Inc. has a fifty-two week low of $31.61 and a fifty-two week high of $43.08. The company has a quick ratio of 1.13, a current ratio of 1.40 and a debt-to-equity ratio of 0.76.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.04). The firm had revenue of $11.68 billion during the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The firm’s revenue was up 11.8% compared to the same quarter last year. During the same period last year, the business earned $0.55 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 4th. Shareholders of record on Friday, May 7th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a yield of 3.90%. Pfizer’s payout ratio is currently 52.88%.

PFE has been the subject of several research analyst reports. The Goldman Sachs Group set a $41.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, April 6th. Mizuho lowered their target price on shares of Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a research note on Wednesday, February 3rd. TheStreet lowered shares of Pfizer from a “b” rating to a “c+” rating in a research note on Friday, March 5th. Berenberg Bank reaffirmed a “neutral” rating and set a $38.00 target price on shares of Pfizer in a research note on Tuesday, March 23rd. Finally, SVB Leerink lowered their target price on shares of Pfizer from $40.00 to $39.00 and set a “market perform” rating for the company in a research note on Thursday, April 1st. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.47.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Recommended Story: What are municipal bonds?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.